These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 32702535)

  • 1. The association between plasma proteomics and incident cardiovascular disease identifies MMP-12 as a promising cardiovascular risk marker in patients with chronic kidney disease.
    Feldreich T; Nowak C; Carlsson AC; Östgren CJ; Nyström FH; Sundström J; Carrero-Roig JJ; Leppert J; Hedberg P; Giedraitis V; Lind L; Cordeiro A; Ärnlöv J
    Atherosclerosis; 2020 Aug; 307():11-15. PubMed ID: 32702535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth differentiation factor 15 (GDF-15) is a potential biomarker of both diabetic kidney disease and future cardiovascular events in cohorts of individuals with type 2 diabetes: a proteomics approach.
    Carlsson AC; Nowak C; Lind L; Östgren CJ; Nyström FH; Sundström J; Carrero JJ; Riserus U; Ingelsson E; Fall T; Ärnlöv J
    Ups J Med Sci; 2020 Feb; 125(1):37-43. PubMed ID: 31805809
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of Proteomics To Investigate Kidney Function Decline over 5 Years.
    Carlsson AC; Ingelsson E; Sundström J; Jesus Carrero J; Gustafsson S; Feldreich T; Stenemo M; Larsson A; Lind L; Ärnlöv J
    Clin J Am Soc Nephrol; 2017 Aug; 12(8):1226-1235. PubMed ID: 28784837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiplex proteomics for prediction of major cardiovascular events in type 2 diabetes.
    Nowak C; Carlsson AC; Östgren CJ; Nyström FH; Alam M; Feldreich T; Sundström J; Carrero JJ; Leppert J; Hedberg P; Henriksen E; Cordeiro AC; Giedraitis V; Lind L; Ingelsson E; Fall T; Ärnlöv J
    Diabetologia; 2018 Aug; 61(8):1748-1757. PubMed ID: 29796748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating proteins as predictors of cardiovascular mortality in end-stage renal disease.
    Feldreich T; Nowak C; Fall T; Carlsson AC; Carrero JJ; Ripsweden J; Qureshi AR; Heimbürger O; Barany P; Stenvinkel P; Vuilleumier N; Kalra PA; Green D; Ärnlöv J
    J Nephrol; 2019 Feb; 32(1):111-119. PubMed ID: 30499038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between levels of pentraxin 3 and incidence of chronic kidney disease in the elderly.
    Sjöberg B; Qureshi AR; Heimbürger O; Stenvinkel P; Lind L; Larsson A; Bárány P; Ärnlöv J
    J Intern Med; 2016 Feb; 279(2):173-9. PubMed ID: 26355706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of fibroblast growth Factor-23 as a correlate of cardiovascular disease among individuals with chronic kidney disease, hypertensives, and healthy controls.
    Abiola BI; Raji YR; Ajayi S; Adeoye AM; Salako BL; Arije A; Kadiri S
    Niger J Clin Pract; 2022 Aug; 25(8):1247-1255. PubMed ID: 35975371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis.
    Black C; Sharma P; Scotland G; McCullough K; McGurn D; Robertson L; Fluck N; MacLeod A; McNamee P; Prescott G; Smith C
    Health Technol Assess; 2010 Apr; 14(21):1-184. PubMed ID: 20441712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD.
    Tuegel C; Katz R; Alam M; Bhat Z; Bellovich K; de Boer I; Brosius F; Gadegbeku C; Gipson D; Hawkins J; Himmelfarb J; Ju W; Kestenbaum B; Kretzler M; Robinson-Cohen C; Steigerwalt S; Bansal N
    Am J Kidney Dis; 2018 Oct; 72(4):519-528. PubMed ID: 29866459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of new biomarkers for atrial fibrillation using a custom-made proteomics chip.
    Lind L; Sundström J; Stenemo M; Hagström E; Ärnlöv J
    Heart; 2017 Mar; 103(5):377-382. PubMed ID: 27609943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and risk of major adverse cardiovascular events in middle-aged patients with chronic kidney disease: a population-based cohort study.
    Chen S; Hsu WY; Lin YN; Wang CY; Wu CH; Chang KH
    Int Urol Nephrol; 2019 Jul; 51(7):1219-1227. PubMed ID: 31020627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The risk trajectory of different cardiovascular morbidities associated with chronic kidney disease among patients with newly diagnosed diabetes mellitus: a propensity score-matched cohort analysis.
    Chao CT; Lee SY; Wang J; Chien KL; Hung KY
    Cardiovasc Diabetol; 2021 Apr; 20(1):86. PubMed ID: 33894776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroblast growth factor 23 and incident CKD in type 2 diabetes.
    Isakova T; Craven TE; Lee J; Scialla JJ; Xie H; Wahl P; Marcovina SM; Byington RP; Wolf M
    Clin J Am Soc Nephrol; 2015 Jan; 10(1):29-38. PubMed ID: 25343949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coronary artery calcium progresses rapidly and discriminates incident cardiovascular events in chronic kidney disease regardless of diabetes: The Multi-Ethnic Study of Atherosclerosis (MESA).
    Shroff GR; Sanchez OA; Miedema MD; Kramer H; Ix JH; Duprez DA; Jacobs DR
    Atherosclerosis; 2020 Oct; 310():75-82. PubMed ID: 32919188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating proteins as predictors of incident heart failure in the elderly.
    Stenemo M; Nowak C; Byberg L; Sundström J; Giedraitis V; Lind L; Ingelsson E; Fall T; Ärnlöv J
    Eur J Heart Fail; 2018 Jan; 20(1):55-62. PubMed ID: 28967680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibroblast growth factor-23 and cardiovascular events in CKD.
    Scialla JJ; Xie H; Rahman M; Anderson AH; Isakova T; Ojo A; Zhang X; Nessel L; Hamano T; Grunwald JE; Raj DS; Yang W; He J; Lash JP; Go AS; Kusek JW; Feldman H; Wolf M;
    J Am Soc Nephrol; 2014 Feb; 25(2):349-60. PubMed ID: 24158986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammation Alters Relationship Between High-Density Lipoprotein Cholesterol and Cardiovascular Risk in Patients With Chronic Kidney Disease: Results From KNOW-CKD.
    Kim JY; Park JT; Kim HW; Chang TI; Kang EW; Ahn C; Oh KH; Lee J; Chung W; Kim YS; Kim SW; Yoo TH; Kang SW; Han SH;
    J Am Heart Assoc; 2021 Aug; 10(16):e021731. PubMed ID: 34369187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers of cardiovascular stress and incident chronic kidney disease.
    Ho JE; Hwang SJ; Wollert KC; Larson MG; Cheng S; Kempf T; Vasan RS; Januzzi JL; Wang TJ; Fox CS
    Clin Chem; 2013 Nov; 59(11):1613-20. PubMed ID: 23873716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of cardiovascular events associated with dipeptidyl peptidase-4 inhibitors in patients with diabetes with and without chronic kidney disease: A nationwide cohort study.
    Huang TL; Hsiao FY; Chiang CK; Shen LJ; Huang CF
    PLoS One; 2019; 14(5):e0215248. PubMed ID: 31112536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma ceruloplasmin, a regulator of nitric oxide activity, and incident cardiovascular risk in patients with CKD.
    Kennedy DJ; Fan Y; Wu Y; Pepoy M; Hazen SL; Tang WH
    Clin J Am Soc Nephrol; 2014 Mar; 9(3):462-7. PubMed ID: 24311705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.